FDA warning letter puts Ipca Labs under fire for widespread data manipulation

FDA inspectors have cracked down on data manipulation and falsification at a number of manufacturing facilities in India, but a new warning letter for three Ipca Laboratories plants shows the problem was rampant there--and enforced by senior managers in the quality-control unit to keep product supply flowing. More from FiercePharmaManufacturing

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.